246 related articles for article (PubMed ID: 29512034)
21. Comparative efficacy and safety of intravenous or subcutaneous belimumab in combination with standard therapy in patients with active systemic lupus erythematosus: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Lupus; 2018 Jan; 27(1):112-119. PubMed ID: 28592201
[TBL] [Abstract][Full Text] [Related]
22. Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
Nikoloudaki M; Nikolopoulos D; Koutsoviti S; Flouri I; Kapsala N; Repa A; Katsimbri P; Theotikos E; Pitsigavdaki S; Pateromichelaki K; Bertsias A; Elezoglou A; Sidiropoulos P; Fanouriakis A; Boumpas D; Bertsias G
Front Immunol; 2022; 13():1074044. PubMed ID: 36685524
[TBL] [Abstract][Full Text] [Related]
23. Post-marketing experiences with belimumab in the treatment of SLE patients.
Askanase AD; Yazdany J; Molta CT
Rheum Dis Clin North Am; 2014 Aug; 40(3):507-17, viii. PubMed ID: 25034159
[TBL] [Abstract][Full Text] [Related]
24. Anti-BLyS Treatment of 36 Israeli Systemic Lupus Erythematosus Patients.
Sthoeger Z; Lorber M; Tal Y; Toubi E; Amital H; Kivity S; Langevitz P; Asher I; Elbirt D; Agmon Levin N
Isr Med Assoc J; 2017 Jan; 19(1):44-48. PubMed ID: 28457114
[TBL] [Abstract][Full Text] [Related]
25. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
Zhang F; Bae SC; Bass D; Chu M; Egginton S; Gordon D; Roth DA; Zheng J; Tanaka Y
Ann Rheum Dis; 2018 Mar; 77(3):355-363. PubMed ID: 29295825
[TBL] [Abstract][Full Text] [Related]
26. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
Doria A; Bass D; Schwarting A; Hammer A; Gordon D; Scheinberg M; Fox NL; Groark J; Stohl W; Kleoudis C; Roth D
Lupus; 2018 Aug; 27(9):1489-1498. PubMed ID: 29807477
[TBL] [Abstract][Full Text] [Related]
27. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
Staveri C; Karokis D; Liossis SC
Semin Arthritis Rheum; 2017 Jun; 46(6):788-790. PubMed ID: 27793432
[TBL] [Abstract][Full Text] [Related]
28. [Recommendations on the use of belimumab in systemic lupus erythematosus. GEAS-SEMI Clinical Practice Guide].
Ramos-Casals M; Ruiz-Irastorza G; Jiménez-Alonso J; Khamashta MA;
Rev Clin Esp (Barc); 2013; 213(1):42-58. PubMed ID: 23266125
[TBL] [Abstract][Full Text] [Related]
29. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
Mosak J; Furie R
Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
[TBL] [Abstract][Full Text] [Related]
30. Belimumab for the treatment of recalcitrant cutaneous lupus.
Vashisht P; Borghoff K; O'Dell JR; Hearth-Holmes M
Lupus; 2017 Jul; 26(8):857-864. PubMed ID: 28121495
[TBL] [Abstract][Full Text] [Related]
31. [Lupus erythematosus treatment with belimumab in daily practice: Retrospective study of 15 patients].
Garval E; Pennaforte JL; Jaussaud R; Servettaz A; Bernard P; Reguiai Z
Ann Dermatol Venereol; 2018 Jan; 145(1):5-12. PubMed ID: 29113694
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.
Borba HH; Wiens A; de Souza TT; Correr CJ; Pontarolo R
BioDrugs; 2014 Apr; 28(2):211-28. PubMed ID: 24190520
[TBL] [Abstract][Full Text] [Related]
33. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus.
Parodis I; Sjöwall C; Jönsen A; Ramsköld D; Zickert A; Frodlund M; Sohrabian A; Arnaud L; Rönnelid J; Malmström V; Bengtsson AA; Gunnarsson I
Autoimmun Rev; 2017 Apr; 16(4):343-351. PubMed ID: 28216072
[TBL] [Abstract][Full Text] [Related]
34. Systemic lupus erythematosus exacerbation following cessation of belimumab treatment.
Furer V; Zisman D; Pokroy-Shapira E; Molad Y; Elkayam O; Paran D
Scand J Rheumatol; 2016; 45(2):103-6. PubMed ID: 26515057
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
[TBL] [Abstract][Full Text] [Related]
36. Subcutaneous and intravenous belimumab in the treatment of systemic lupus erythematosus: a review of data on subcutaneous and intravenous administration.
Poh YJ; Baptista B; D'Cruz DP
Expert Rev Clin Immunol; 2017 Oct; 13(10):925-938. PubMed ID: 28847197
[TBL] [Abstract][Full Text] [Related]
37. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: A systematic review.
Sciascia S; Radin M; Yazdany J; Levy RA; Roccatello D; Dall'Era M; Cuadrado MJ
Autoimmun Rev; 2017 Mar; 16(3):287-293. PubMed ID: 28147262
[TBL] [Abstract][Full Text] [Related]
39. Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: a case series.
Gualtierotti R; Borghi MO; Gerosa M; Schioppo T; Larghi P; Geginat J; Meroni PL
Clin Exp Rheumatol; 2018; 36(4):643-647. PubMed ID: 29533753
[TBL] [Abstract][Full Text] [Related]
40. Patient- and Physician-reported Satisfaction With Systemic Lupus Erythematosus Treatment in US Clinical Practice.
Pascoe K; Lobosco S; Bell D; Hoskin B; Chang DJ; Pobiner B; Ramachandran S
Clin Ther; 2017 Sep; 39(9):1811-1826. PubMed ID: 28803702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]